8-K: Merit Medical Acquires Biolife Delaware, L.L.C. for $120 Million

Merit Medical Systems, Inc. has acquired Biolife Delaware, L.L.C. for $120 million in cash, expanding its hemostasis solutions portfolio.

Summary

• Merit Medical Systems acquired Biolife Delaware, L.L.C. for $120 million on May 20, 2025.
• The acquisition was funded with available cash on hand.
• Biolife manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
• Merit expects the acquisition to add approximately $18 million of revenue on an annualized basis beginning in fiscal year 2026.
• The acquisition is projected to be accretive to non-GAAP gross margin and non-GAAP operating margin in 2025.
• The acquisition is projected to be slightly accretive to non-GAAP net income and non-GAAP earnings per share in 2026.
• Merit has updated its full-year 2025 financial guidance to include the projected impact of the Biolife acquisition.
• Merit reaffirms its full-year 2025 financial guidance previously issued on April 24, 2025.
• Merit now expects net sales of $1.480 $1.501 billion for the year ending December 31, 2025.
• Non-GAAP earnings per share are expected to be $3.28 $3.41 for the year ending December 31, 2025.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a strategic acquisition that expands Merit's product portfolio and is expected to be accretive to margins in the future. However, there are some short-term dilutive effects on earnings.

Positives

• The acquisition expands Merit's hemostasis solutions portfolio.
• Biolife's products are clinically validated and address a $350 million global market.
• The acquisition is expected to be accretive to non-GAAP gross and operating margins in 2025.
• The acquisition is expected to be slightly accretive to non-GAAP net income and non-GAAP earnings per share in 2026.
• Merit believes it is well-positioned to further develop and expand the reach of Biolife's product lines.

Negatives

• The acquisition is projected to be dilutive to Merit's full-year 2025 GAAP net income and GAAP earnings per share.
• The acquisition is projected to dilute Merit's previously forecasted non-GAAP net income and non-GAAP earnings per share from May 20, 2025 through December 31, 2025, inclusive of approximately $3.0 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $7.2 million of non-cash and non-recurring transaction-related expenses.

Risks

• The integration of Biolife's business and operations may present challenges.
• Merit may not achieve the projected financial results, product development, and other anticipated benefits of the acquisition.
• The updated full-year 2025 financial guidance is subject to risks and uncertainties identified in Merit's filings with the SEC.
• Merit's actual results may differ materially from anticipated results.

Future Outlook

Merit has updated its full-year 2025 financial guidance to include the projected impact of the Biolife acquisition and reaffirms its prior guidance issued on April 24, 2025. The company anticipates the transaction will be slightly dilutive to full-year 2025 non-GAAP profitability but believes the financial profile of the acquisition is very attractive and consistent with its goals.

Management Comments

• Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer, stated that the acquisition enhances the portfolio of hemostatic solutions offered to clinicians.
• Mr. Lampropoulos believes Merit is well-positioned to further develop and expand the reach of Biolife's product lines.

Industry Context

The acquisition of Biolife positions Merit to compete more effectively in the hemostasis solutions market, complementing its existing product portfolio and expanding its reach in interventional radiology, cardiology, and other percutaneous procedures.

Comparison to Industry Standards

• The $350 million global market opportunity for StatSeal and WoundSeal products suggests a significant potential for growth, comparable to other players in the advanced wound care and hemostasis market.
• Companies like Baxter International and Becton Dickinson also offer hemostasis products, indicating a competitive but growing market.

Stakeholder Impact

• Shareholders may benefit from the expected revenue growth and margin expansion.
• Clinicians will have access to a broader range of hemostatic solutions.
• Patients may benefit from improved post-procedure care and reduced complications.

Next Steps

• Merit will integrate the Biolife business and operations.
• Merit will further develop and expand the reach of Biolife's product lines.
• Merit will discuss the acquisition in further detail on its second quarter earnings report on July 30, 2025.

Key Dates

Keywords

acquisition, Biolife, Merit Medical, hemostasis, StatSeal, WoundSeal, financial guidance, merger